



Nassim Nouri
NuGEN Technologies, Inc.
650-590-3678
nnouri@nugeninc.com

Media contact:
Richard A. Howell
SVM Group for NuGEN
650-346-7425
rhowell@svmgroup.com

NuGEN Technologies Expands Management Team with Three New Appointments

Company adds CFO, VP Commercial Operations and Senior Director of Customer Solutions

SAN CARLOS, Calif. – December 12, 2005 – NuGEN Technologies, Inc., a privately held company that develops and commercializes the new standard in nucleic acid amplification and labeling systems, today announced that it has made several key executive appointments to position the company for further growth of their Ovation™ and WT-Ovation™ family of products.

Ms. Nancy Pecota has been appointed Chief Financial Officer. With more than twenty years of proven financial management experience, Nancy has spent the last few years as an executive financial consultant specializing in early and mid-stage life science companies. Previously, she had served as vice president of finance and administration at Signature Bioscience, Inc. and as a senior director of finance and accounting at ACLARA BioSciences, Inc. In that role, she was an integral part of the management team during their initial public offering, raising over \$200 million. Nancy has also held senior finance roles at dpiX, Inc., Xerox Corporation and Westinghouse Corporation. Nancy received her B.S. in Economics from San Jose State University.

Dr. Sue Pandey has been appointed Vice President of Commercial Operations. Sue has over twenty years of life science experience, first as a research scientist at Chevron and then initiating her field sales career with Zymark. Her management career began at Hewlett Packard/Agilent Technologies and most recently she has held the position of global head of sales at GE Healthcare, where she was responsible for managing the CodeLink™ commercial organization. Sue holds a Ph.D. in Chemistry from U.C. Irvine and an M.B.A. from Pepperdine.

Dr. Gianfranco DeFeo has been appointed Senior Director of Customer Solutions. Gianfranco's 15+ years of life science experience began with his postdoctoral work at U.C.S.F. He then joined PE/ Applied Biosystems as a field applications scientist. In 1998, he joined Affymetrix where he held technical management roles as field applications manager and director of genomic collaborations. Most recently, Gianfranco managed the global technical support organization at Quantum Dot. Gianfranco holds a Ph.D. from U.C.L.A.

"The fact that Nancy, Sue and Gianfranco have chosen to join NuGEN is a great validation of the company's team and technology," said Elizabeth A. Hutt, Chief Executive Officer of NuGEN. "We look forward to the contribution of these top industry professionals to further solidify NuGEN as the leader in nucleic acid amplification technology."

About NuGEN Technologies Inc.

NuGEN Technologies is focused on the development and commercialization of sensitive, rapid and cost-effective amplification and detection systems for genomic and proteomic research. The company's technologies enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies. NuGEN's proprietary SPIA™ and Ribo-SPIA™ amplification and labeling system for DNA and RNA based applications, form the foundation for a wide range of



methods and products used by life scientists. The Ovation™ amplification and labeling system, the company's first commercially available product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis. Based in San Carlos, CA, NuGEN has a world-class investor syndicate, several collaborations with leading academic and commercial organizations and a management team with significant experience developing and marketing products for research or clinical diagnostic applications.

NuGEN, Ovation, SPIA and Ribo-SPIA are trademarks or service marks of NuGEN Technologies, Inc. All other marks are the property of their respective owners.

This press release contains forward-looking statements that are subject to risks and uncertainties, including continued growth in demand by researchers for total RNA analysis, continued use of oligo and cDNA microarrays, acceptance by researchers of the Company's technologies and products, and competition from existing and newly developed products. Accordingly, actual results may differ materially from those anticipated. These forward-looking statements represent the Company's current expectations as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

###